Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986297 | 1.00 | LTA4H (0.37) | LTA4HCA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17986340 | 0.89 | LTA4H (0.43) | LTA4HMEN1KMT2AKCNA3MAPT | |
| SCHEMBL17986339 | 0.89 | LTA4H (0.43) | LTA4HMEN1KMT2AKCNA3MAPT | |
| SCHEMBL17986234 | 0.83 | LTA4H (0.38) | LTA4HCA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17986235 | 0.83 | LTA4H (0.38) | LTA4HCA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5958244 | 0.73 | TSHR (0.40) | TSHRMAPTL3MBTL1 | |
| SCHEMBL5958246 | 0.73 | TSHR (0.40) | TSHRMAPTL3MBTL1 | |
| SCHEMBL7363159 | 0.73 | LTA4H (0.45) | LTA4HCA4KCNA3TSHRL3MBTL1 | |
| SCHEMBL4151571 | 0.72 | CA4 (0.42) | LTA4HCA4KCNA3TSHRL3MBTL1 | |
| SCHEMBL4151573 | 0.72 | CA4 (0.42) | LTA4HCA4KCNA3TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | LTA4H 1589/4885CA4 1953/4885CHRNB2 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.